Latest Casdin Capital, LLC Stock Portfolio
Casdin Capital, LLC Performance:
2025 Q3: 18.75%YTD: 2.46%2024: 21.16%
Performance for 2025 Q3 is 18.75%, and YTD is 2.46%, and 2024 is 21.16%.
About Casdin Capital, LLC and 13F Hedge Fund Stock Holdings
Casdin Capital, LLC is a hedge fund based in NEW YORK, NY. On 31-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $2.7 Billions. In it's latest 13F Holdings report, Casdin Capital, LLC reported an equity portfolio of $1.2 Billions as of 30 Sep, 2025.
The top stock holdings of Casdin Capital, LLC are SMFR, BLFS, RVMD. The fund has invested 27% of it's portfolio in GENEDX HOLDINGS CORP and 14.3% of portfolio in BIOLIFE SOLUTIONS INC.
The fund managers got completely rid off VERVE THERAPEUTICS INC (VERV), CODEXIS INC (CDXS) and SAREPTA THERAPEUTICS INC (SRPT) stocks. They significantly reduced their stock positions in ALNYLAM PHARMACEUTICALS INC (ALNY), ILLUMINA INC (ILMN) and GENEDX HOLDINGS CORP (SMFR). Casdin Capital, LLC opened new stock positions in TEMPUS AI INC, ARS PHARMACEUTICALS INC (SBTX) and UNITEDHEALTH GROUP INC (UNH). The fund showed a lot of confidence in some stocks as they added substantially to PRIME MEDICINE INC, BEAM THERAPEUTICS INC (BEAM) and STANDARD BIOTOOLS INC (LAB).
The top stock holdings of Casdin Capital, LLC are SMFR, BLFS, RVMD. The fund has invested 27% of it's portfolio in GENEDX HOLDINGS CORP and 14.3% of portfolio in BIOLIFE SOLUTIONS INC.
The fund managers got completely rid off VERVE THERAPEUTICS INC (VERV), CODEXIS INC (CDXS) and SAREPTA THERAPEUTICS INC (SRPT) stocks. They significantly reduced their stock positions in ALNYLAM PHARMACEUTICALS INC (ALNY), ILLUMINA INC (ILMN) and GENEDX HOLDINGS CORP (SMFR). Casdin Capital, LLC opened new stock positions in TEMPUS AI INC, ARS PHARMACEUTICALS INC (SBTX) and UNITEDHEALTH GROUP INC (UNH). The fund showed a lot of confidence in some stocks as they added substantially to PRIME MEDICINE INC, BEAM THERAPEUTICS INC (BEAM) and STANDARD BIOTOOLS INC (LAB).
Casdin Capital, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Casdin Capital, LLC made a return of 18.75% in the last quarter. In trailing 12 months, it's portfolio return was 2.6%.
New Buys
| Ticker | $ Bought |
|---|---|
| tempus ai inc | 23,739,000 |
| ars pharmaceuticals inc | 16,080,000 |
| unitedhealth group inc | 8,632,500 |
| incyte corp | 8,481,000 |
| bridgebio oncology therapeut | 3,269,170 |
New stocks bought by Casdin Capital, LLC
Additions
| Ticker | % Inc. |
|---|---|
| prime medicine inc | 102 |
| structure therapeutics inc | 26.94 |
| beam therapeutics inc | 10.34 |
| standard biotools inc | 1.95 |
| avidity biosciences inc | 0.28 |
Additions to existing portfolio by Casdin Capital, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| alnylam pharmaceuticals inc | -32.52 |
| illumina inc | -18.6 |
| genedx holdings corp | -14.26 |
| biolife solutions inc | -12.97 |
| revolution medicines inc | -8.33 |
| relay therapeutics inc | -0.5 |
Casdin Capital, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| codexis inc | -17,568,000 |
| verve therapeutics inc | -45,993,300 |
| sarepta therapeutics inc | -16,930,700 |
| syndax pharmaceuticals inc | -6,084,000 |
| agios pharmaceuticals inc | -3,326,000 |
| eli lilly & co | -6,626,000 |
Casdin Capital, LLC got rid off the above stocks
Sector Distribution
Casdin Capital, LLC has about 58.7% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 58.7 |
| 28.4 | |
| Others | 11.9 |
| Consumer Defensive | 1.1 |
Market Cap. Distribution
Casdin Capital, LLC has about 7.4% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 57.2 |
| MID-CAP | 22.7 |
| UNALLOCATED | 11.9 |
| LARGE-CAP | 7.4 |
Stocks belong to which Index?
About 48.6% of the stocks held by Casdin Capital, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 51.4 |
| RUSSELL 2000 | 43 |
| S&P 500 | 5.6 |
Casdin Capital, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Casdin Capital, LLC
Casdin Capital, LLC has 32 stocks in it's portfolio. About 84.5% of the portfolio is in top 10 stocks. ILMN proved to be the most loss making stock for the portfolio. SMFR was the most profitable stock for Casdin Capital, LLC last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ABSI | absci corporation | 0.25 | 973,260 | 2,958,710 | unchanged | 0.00 | ||
| AGIO | agios pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALNY | alnylam pharmaceuticals inc | 2.09 | 55,000 | 25,080,000 | reduced | -32.52 | ||
| BEAM | beam therapeutics inc | 3.24 | 1,600,000 | 38,832,000 | added | 10.34 | ||
| BLFS | biolife solutions inc | 14.27 | 6,707,160 | 171,100,000 | reduced | -12.97 | ||
| CDXS | codexis inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| DNA | ginkgo bioworks holdings inc | 0.04 | 36,493 | 532,068 | unchanged | 0.00 | ||
| DNLI | denali therapeutics inc | 1.08 | 890,000 | 12,922,800 | unchanged | 0.00 | ||
| EXAS | exact sciences corp | 0.41 | 90,000 | 4,923,900 | unchanged | 0.00 | ||
| GH | guardant health inc | 0.52 | 100,000 | 6,248,000 | unchanged | 0.00 | ||
| GLUE | monte rosa therapeutics inc | 0.05 | 86,014 | 637,364 | unchanged | 0.00 | ||
| HIMS | hims & hers health inc | 1.09 | 230,000 | 13,045,600 | unchanged | 0.00 | ||
| ILMN | illumina inc | 4.16 | 525,000 | 49,859,200 | reduced | -18.6 | ||
| INCY | incyte corp | 0.71 | 100,000 | 8,481,000 | new | |||
| IPSC | century therapeutics inc | 0.05 | 1,228,190 | 611,639 | unchanged | 0.00 | ||
| LAB | standard biotools inc | 8.41 | 77,558,900 | 100,827,000 | added | 1.95 | ||
| LLY | eli lilly & co | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| PACB | pacific biosciences calif in | 0.08 | 723,767 | 926,422 | unchanged | 0.00 | ||
| RLAY | relay therapeutics inc | 4.94 | 11,341,400 | 59,202,000 | reduced | -0.5 | ||
| RNA | avidity biosciences inc | 6.47 | 1,780,000 | 77,554,600 | added | 0.28 | ||